# Favipiravir in High-risk COVID-19 Patients

> **NCT04818320** · PHASE3 · COMPLETED · sponsor: **Penang Hospital, Malaysia** · enrollment: 500 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Favipiravir

## Key facts

- **NCT ID:** NCT04818320
- **Lead sponsor:** Penang Hospital, Malaysia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-16
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-13
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818320, "Favipiravir in High-risk COVID-19 Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04818320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*